Dr. Jonathan Yong joined Tremeau in 2019 as the Head of Medical Affairs.

Prior to joining Tremeau he most recently served as the Worldwide Medical Head of Pipeline Therapy Areas at Biogen, Inc. with responsibility for a portfolio of programs including pain, tauopathies, stroke, ophthalmology and gene therapies. During his tenure at Biogen he was also responsible for the build out of the Worldwide Neuromuscular and Rare Diseases medical group and pioneered the early access programs and launch for SPINRAZA in Spinal Muscular Atrophy.

Prior to Biogen Dr. Yong served in medical roles of increasing responsibility at country, regional and Global levels with Merck & Co., Inc. in Europe and the US. Dr. Yong supported a range of products including ARCOXIA in pain and BRIDION and EMEND in acute hospital and specialty care therapy areas. He has led multiple Global product launches and additionally worked in oncology, cardiovascular and respiratory therapy areas with a proven record in demonstrating clinical value in support of patient access to treatments and achieving reimbursement.

Jonathan received his MD from King’s College London and trained in Anesthesiology and Intensive Care.